Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EXECUTIVE VICE PRESIDENT | November 15, 2021 | November 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date November 15, 2021 · Filed November 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 76,087 |
Reported balance
After 2021-11-15 transaction · row 1
1 source rowRow 1 · 2021-11-15 · Sale · Disposed 10,000 · Balance 76,087 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.03, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 1,543 |
Reported balance
Holding disclosure · report date 2021-11-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,543 F2: Balance in the Abbott Laboratories Stock Retirement Trust as of November 15, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.03, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: Balance in the Abbott Laboratories Stock Retirement Trust as of November 15, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2016 Filed Feb 23, 2016 22:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 605 | $38.53 | $23,310.65 |
DisclosureSEC source: 0001179110-16-019897 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,703 Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 22:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 174,657 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-16-019897 · edgar.xml · derivative · entry 2 LANE ANDREW H · CIK 0001643735 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,657 Underlying: Common shares · 174,657 shares Expires 2026-02-18 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 58,219 on 02/19/2017, 58,219 on 02/19/2018, and 58,219 on 02/19/2019. Read SEC document |
| June 01, 2015 Filed Jun 3, 2015 21:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 114,692 | $0.00 Strike: $48.90 | $0.00 |
DisclosureSEC source: 0001179110-15-009076 · edgar.xml · derivative · entry 1 LANE ANDREW H · CIK 0001643735 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,692 Underlying: Common shares · 114,692 shares Expires 2025-05-31 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,231 on 6/1/2016, 38,230 on 6/1/2017, and 38,231 on 6/1/2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.